Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alternative pathway of complement in multiple myeloma.

E H Kraut, A L Sagone

    American Journal of Hematology
    |December 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma.

    Leukemia research·2007
    Same author

    Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review.

    Haemophilia : the official journal of the World Federation of Hemophilia·2007
    Same author

    Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus.

    Annals of oncology : official journal of the European Society for Medical Oncology·2005
    Same author

    Phase II study of pyrazoloacridine in metastatic renal cell carcinoma.

    Investigational new drugs·2001
    Same author

    Splenic angiosarcoma and iron deficiency anemia in a 43-year-old man.

    Southern medical journal·2001
    Same author

    NCCN Practice Guidelines for Acute Myelogenous Leukemia.

    Oncology (Williston Park, N.Y.)·2001

    The alternative pathway of complement is often abnormal in multiple myeloma patients, potentially increasing infection risk. This study investigated complement function in 18 myeloma patients, finding significant abnormalities.

    Area of Science:

    • Immunology
    • Hematology
    • Complement System Biology

    Background:

    • Multiple myeloma is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
    • The complement system, a crucial part of innate immunity, plays a role in host defense.
    • Dysregulation of the complement system, particularly the alternative pathway, may impact infection susceptibility in immunocompromised patients.

    Purpose of the Study:

    • To investigate the functional activity of the alternative pathway of complement in patients with multiple myeloma.
    • To determine the correlation between alternative pathway abnormalities and clinical parameters in multiple myeloma.

    Main Methods:

    • Studied 16 newly diagnosed and 2 previously treated patients with multiple myeloma.
    • Assessed the functional activity of the alternative pathway of complement.

    Related Experiment Videos

  • Measured levels of alternative pathway components.
  • Correlated complement activity with monoclonal protein concentration.

    • Main Results:

    • Functional activity of the alternative pathway was abnormal in 10 out of 18 patients (55%).
    • Abnormalities correlated with depressed component levels in 3 patients; etiology was undetermined in 7.
    • An inverse correlation was observed between alternative pathway activity and monoclonal protein concentration.

    Conclusions:

    • The alternative pathway of complement is frequently dysfunctional in multiple myeloma.
    • This complement defect may represent an additional factor predisposing multiple myeloma patients to severe infections.
    • Further research is warranted to elucidate the mechanisms underlying complement dysregulation in multiple myeloma.